Regions – Page 143 – pharmaceutical daily

June 19, 2019 Off

Uterine Fibroids Market Spotlight, 2026 – Repros Therapeutics has the Highest Number of Completed Clinical Trials

It is estimated that there were approximately 92.2
million prevalent cases of uterine fibroids worldwide in females aged
15 years and over, and forecasts that number to increase to 102.7
million prevalent cases by 2026.

June 19, 2019 Off

Global Peripheral T-Cell Lymphoma (PTCL) Market Spotlight 2018-2026

By BusinessWire

Estimation says that in 2017, there were approximately 19,950
incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
forecasts that number to increase to 23,880 incident cases by 2026.

June 19, 2019 Off

Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023

By BusinessWire

Therapeutics Market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe) is witnessed to
grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”

June 19, 2019 Off

Ironwood, Allergan with positive topline data from LINZESS testing in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

By BusinessWire

– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –

June 19, 2019 Off

ObsEva clears issues with FDA over nolasiban

By Dino Mustafić

ObsEva’s has recently cleared with the U.S. Food and Drug Administration (FDA) several important development issues for its oral oxytocin receptor antagonist nolasiban, which enables it to begin its U.S. Phase 3 clinical trial (IMPLANT 3) in the fourth quarter of this year or early 2020.

June 18, 2019 Off

Novigenix welcomes to the Board doctor Francois Martelet, as Non-Executive Director

By BusinessWire

Novigenix SA, a leading Immuno-Transcriptomics company that develops and
commercializes products for early cancer detection and precision
medicine, today announced the appointment of Francois Martelet, M.D., to
its Board of Directors as a non-executive director. Dr. Martelet has
over 25 years’ experience at both corporate and operational level in
pharmaceutical and biotech companies.

June 17, 2019 Off

Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis

By Dino Mustafić

Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).

June 17, 2019 Off

IVERIC bio, Catalent’s Paragon Gene Therapy in deal for Orphan Inherited Retinal Diseases

By BusinessWire

NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into…

June 17, 2019 Off

ArQule’s data confirm miransertib’s potential for treating PS and PROS patients

By BusinessWire

Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib…

June 17, 2019 Off

Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

By BusinessWire

Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use,…